ReviewMedicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents2026
Coumarin derivatives as HIV-1 inhibitors: mechanistic insights and structure-activity relationships.
Review in Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Coumarin is a versatile scaffold occurring extensively in abundant natural compounds and synthetic pharmaceuticals. Coumarin derivatives have been proven to inhibit multiple stages of HIV-1 replication, and their unique structures enable them to interact with diverse targets involved in the HIV-1 replication cycle, thereby exerting potent antiviral activity. Currently, HIV-1 inhibitors with novel structures and mechanisms are in urgent need to overcome the existing challenges of drug resistance, safety, and efficacy. Based on the characteristics of the retroviral life cycle, this paper reviews the research progress of coumarin derivatives over the past two decades, aiming to provide valuable insights into the structure-activity relationships (SARs) and design strategies for novel coumarin-based HIV-1 inhibitors in the future.
Indexed as
Identifiers
42446682What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.